Company Profile

Tomegavax Inc
Profile last edited on: 3/26/18      CAGE: 6EXF1      UEI: NUE6Q16X2GL1

Business Identifier: Vaccines and immunotherapies for chronic and recurring viral infections
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

505 Nw 185th Avenue
Beaverton, OR 97006
   (425) 830-5805
Location: Single
Congr. District: 01
County: Washington

Public Profile

A spinoff originally from Oregon Health & Science University, in January 2017. TomegaVax was acquired by San Francisco based start-up biotech firm Vir Biotechnology in which ARCH Venture Partners and the Bill & Melinda Gates Foundation are among the lead investors. TomegaVax Inc. is an immunotherapy company organzied around developing cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis - — diseases where there’s no natural immunity in humans and traditional vaccine mechanisms don’t work. The approach is to use the CMV virus to trigger a persistent immune response and redirect it to other pathogens.The firm applies a vaccine technology platform to areas of unmet medical need and is focused on the preclinical and clinical development of vaccines and immunotherapies for chronic and recurring viral infections. Tomegavas research team will remain intact and contnue to work in the the OTRADI Bioscience Incu

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 2 NIH $1,982,523
Project Title: A Cytomegalovirus-Based Therapeutic Vaccine for Chronic Hepatitis B
2017 2 NIH $2,101,184
Project Title: An Effector Memory T Cell-Based Therapeutic Cervical Cancer Vaccine
2016 2 NIH $3,265,238
Project Title: Spread-Deficient Hcmv-Vectored Vaccines
2016 1 NIH $224,959
Project Title: A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine
2014 1 NIH $299,863
Project Title: CMV Vectored Herpes Simplex Vaccine

Key People / Management

  Klaus Frueh -- Founder, President and Chief Scientific Officer

  Eric Bruening -- Chief Operating Officer

  Thomas Evans -- Chief Medical Officer

  Emily Elizabeth Marshall

  Daniel N Streblow

  Sanjay Vashee